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Integrative Physiology
Serotonin and Angiotensin Receptors in Cardiac Fibroblasts
Coregulate Adrenergic-Dependent Cardiac Hypertrophy
Fabrice Jaffre´, Philippe Bonnin, Jacques Callebert, Haythem Debbabi, Vincent Setola, Ste´phane Doly,
Laurent Monassier, Bertrand Mettauer, Burns C. Blaxall, Jean-Marie Launay, Luc Maroteaux
Abstract—By mimicking sympathetic stimulation in vivo, we previously reported that mice globally lacking serotonin
5-HT2B receptors did not develop isoproterenol-induced left ventricular hypertrophy. However, the exact cardiac cell
type(s) expressing 5-HT2B receptors (cardiomyocytes versus noncardiomyocytes) involved in pathological heart
hypertrophy was never addressed in vivo. We report here that mice expressing the 5-HT2B receptor solely in cardiomyocytes,
like global 5-HT2B receptor–null mice, are resistant to isoproterenol-induced cardiac hypertrophy and dysfunction, as well as
to isoproterenol-induced increases in cytokine plasma-levels. These data reveal a key role of noncardiomyocytes in
isoproterenol-induced hypertrophy in vivo. Interestingly, we show that primary cultures of angiotensinogen null adult cardiac
fibroblasts are releasing cytokines on stimulation with either angiotensin II or serotonin, but not in response to isoproterenol
stimulation, demonstrating a critical role of angiotensinogen in adrenergic-dependent cytokine production. We then show a
functional interdependence between AT1Rs and 5-HT2B receptors in fibroblasts by revealing a transinhibition mechanism that
may involve heterodimeric receptor complexes. Both serotonin- and angiotensin II–dependent cytokine production occur via
a Src/heparin-binding epidermal growth factor–dependent transactivation of epidermal growth factor receptors in cardiac
fibroblasts, supporting a common signaling pathway. Finally, we demonstrate that 5-HT2B receptors are overexpressed in
hearts from patients with congestive heart failure, this overexpression being positively correlated with cytokine and
norepinephrine plasma levels. Collectively, these results reveal for the first time that interactions between AT1 and 5-HT2B
receptors coexpressed by noncardiomyocytes are limiting key events in adrenergic agonist-induced, angiotensin-dependent
cardiac hypertrophy. Accordingly, antagonists of 5-HT2B receptors might represent novel therapeutics for sympathetic
overstimulation-dependent heart failure. (Circ Res. 2009;104:113-123.)
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Cardiac hypertrophy is a physiological adaptation of theheart to increased workload. Recent data challenged the
widely held belief that cardiac hypertrophy is a necessary
compensatory mechanism to maintain normal heart func-
tion.1,2 When sustained and extensive, cardiac hypertrophy
can lead to maladaptation and progressive dysfunction lead-
ing to heart failure secondary to cardiomyocyte apoptosis and
fibrosis.3 In addition to biomechanical stress, several neuro-
humoral factors acting via G protein–coupled receptors
(GPCRs), including -adrenergic (-AR), endothelin and
angiotensin (Ang) II type 1 (AT1R) receptors have been
identified as potent inducers of cardiac hypertrophy.4–7
The chronic adrenergic stimulation experienced by patients
with congestive heart failure (CHF) is a strong predictor of
morbidity and mortality. Norepinephrine, through stimulation
of -ARs, is a well-known trigger of cardiac hypertrophy.
The extent of left ventricular dysfunction in human pathology
correlates to plasma norepinephrine concentration indepen-
dently of arterial blood pressure.8 Plasma levels of cytokines
such as tumor necrosis factor (TNF)- and interleukin (IL)-69
or transforming growth factor (TGF)-110 are also signifi-
cantly increased in primary idiopathic hypertrophic cardio-
myopathy. Noncardiomyocyte (cardiac fibroblast) stimula-
tion by adrenergic agonists or Ang II can release growth
factors,11 endothelin-1, and cytokines including TNF-, IL-6,
IL-1, and TGF-1.12–14 Interestingly, several authors have
demonstrated marked in vitro release of these hypertrophic
factors by cardiac fibroblasts and suggested a causal link
between this release and cardiomyocyte hypertrophy. The hy-
pertrophic capacity of cytokines was also validated in vivo by
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the observation that mice with cardiac-restricted overexpression
of TNF-, IL-6, or IL-1 exhibited cardiac hypertrophy.15–17
The question of whether -AR stimulation promotes
pathological cardiac hypertrophy by a direct effect on myo-
cytes and/or nonmyocytes remains debatable. In vitro, most
of the investigators used neonatal rat cardiomyocytes and
found that the -AR agonist, isoproterenol (ISO), leads to a
mild hypertrophy of these cells, the hypertrophy being
stronger in presence of cardiac fibroblast-conditioned
medium.18 However, it was reported that ISO had no hyper-
trophic effects on adult rat myocytes,19,20 suggesting that
noncardiomyocytes could participate in -adrenergic–depen-
dent cardiac hypertrophy in an in vivo adult context.
Using a genetic approach, we previously showed that
serotonin 5-HT2B receptors (5-HT2BRs) have a trophic action
on newborn cardiomyocytes in vitro21 and by -myosin
heavy chain (-MHC)-dependent 5-HT2BR overexpression in
cardiomyocytes in vivo.22 The initial cardiomyopathy of
5-HT2BR mutant mice is compensated over time in the
absence of hypertrophic stage.23 Thus, we studied their response
to a pathological hypertrophic stimulus using chronic ISO
infusion as a model of sympathetic stimulation in vivo. We
reported that either total genetic (5-HT2BR mutant mice) or
pharmacological (SB206553 or SB215505, 5-HT2BR antago-
nists) blockade of 5-HT2BR function completely prevented
ISO-induced cardiac hypertrophy.13 Recently, 5-HT2BRs were
shown to be required for left ventricular hypertrophy in another
model of cardiac hypertrophy (Ang II chronic infusion).24
Nevertheless, neither the exact cardiac cells requiring 5-HT2BRs
(cardiomyocytes versus fibroblasts), the receptor crosstalk nor
their transduction pathway has been addressed in in vivo models
of pathological cardiac hypertrophy.
The purpose of this study was to determine: (1) whether
5-HT2BR expression in cardiomyocytes is required for ISO-
induced left ventricular hypertrophy; (2) whether Ang II
participates in -AR-dependent cardiac hypertrophy in vivo;
(3) which epistatic relationships exist between -AR–, AT1R–,
and 5-HT2BR–dependent hypertrophic factor release; and (4)
whether similar mechanisms could be found in human CHF.
Figure 1. 5-HT2BRs and AT1Rs
colocalization in fibroblasts. a,
Fixed frozen human left ven-
tricle sections were immuno-
stained using antisera against
5-HT2BR or AT1R. Single con-
focal plane observation
reveals that 5-HT2BR localiza-
tion (5-HT2B) is mainly colo-
calized (merge) with AT1R-
positive cells (AT1); top scale
bar, 10 m; bottom images,
higher magnification (scale
bar, 5 m). b, Fixed human
left ventricle sections were
immunostained using antisera
against 5-HT2BR or vimentin.
Single confocal plane obser-
vation reveals that 5-HT2BR is
mainly colocalized (merge)
with vimentin-positive cells;
scale bar, 5 m. Radioligand
binding revealed the expression
level (Bmax) of 5-HT2ARs,
5-HT2BRs, 5-HT2CRs, or AT1Rs
in primary culture of adult
mouse cardiac fibroblasts (c) or
cardiomyocytes (d) of wild-type
and mutant mice for 5-HT2BRs
(n3 independent cultures;
each determination in triplicate).
Results are meansSEM in
maximal density of receptor
sites Bmax expressed as
fmol/mg of membranes proteins
*P0.05; NS, P0.05 vs wild-
type mice.
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Materials and Methods
Generation of 5-HT2BR Transgenic Mice
and Genotyping
Generation of -MHC-5-HT2B/ (Tg) mice and 5-HT2B/ mice
has been described previously.22,25 All animal experiments were
performed in accordance with institutional guidelines and European
regulations.
Induction of Cardiac Hypertrophy by ISO
In 11-week-old male mice, ISO (30 mg/kg per day), was delivered
for 7 days by miniosmotic pumps (1007D, Alzet Corp) implanted
subcutaneously under anesthesia (0.75% isoflurane).
Cardiovascular Phenotyping by Echocardiography
Left ventricular dimension and heart rate were assessed before and
after ISO infusion under isoflurane anesthesia (0.75%) by echocar-
Figure 2. Rescued expression of 5-HT2BRs in cardiomyocytes in vivo. a, Top, Restriction map of the 5-HT2B receptor genomic locus of inter-
est. Middle, Mutated locus after homologous recombination in / mice. Bottom, Mouse -MHC-5-HT2B transgene. b, The different geno-
types were detected by Southern blot analysis. The probe (P) detects a 9.3-kbp BglII fragment from wild-type DNA, whereas it is reduced to
3.2 kbp in the homologous recombined allele and to 2.8 kbp for -MHC2B transgene. Radioligand binding revealed the expression level of
5-HT2BRs as maximal density of receptor sites (Bmax) in heart of different transgenics (c) (n6 to 8 mice, each determination in triplicate).
Results are meansSEM in maximal density of receptor site Bmax expressed as fmol/mg of membranes proteins. *P0.05 vs wild-type con-
trol mice (5-HT2BR
/): transgenic -MHC-5-HT2BR over wild-type (Tg; 5-HT2B
/); transgenic -MHC-5-HT2BR over heterozygous (Tg;
5-HT2B
/); transgenic -MHC-5-HT2BR over homozygous (Tg; 5-HT2B
/); global homozygous 5-HT2B
/ mice.
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diography.13 After echocardiographic analysis, mice were euthanized
by CO2 and weighed.
Analysis of 5-HT2R and AT1R Expression by
Binding Assays
Membrane proteins prepared from heart ventricles or from adult
mouse cardiac fibroblast or myocytes primary cultures were ana-
lyzed by binding studies to assess receptor expression.23
Patients
Cardiac samples were obtained from explant grafts except for normal
controls, the tissue of which was obtained from donors without
recipient. ELISAs for plasma concentration for cytokines were
performed. The local ethical committee (Comite´ Consultatif de
Protection des Personnes se Pre´tant a` la Recherche Biome´dicale,
CCPPRB d’Alsace) approved the study, and all patients gave their
informed consent before tissue collection and plasma collection. For
frozen human heart sections, all harvest and use of human tissue was
performed in accordance with NIH and University of Rochester
Medical Center institutional review board guidelines.
Adult Cardiac Fibroblasts Primary Culture
Cultures of ventricular noncardiomyocytes were obtained by differ-
ential plating from dissociated heart of male adults mice (10 to 12
weeks) or from neonatal rat hearts (3 to 4 days). Cardiac fibroblasts
used during early passages were identified by characteristic mor-
phology and positive staining with antibody to vimentin (90%)13
and negative staining for macrophage marker F4/8026 (1%) (Figure
II in the online data supplement). One day before the experiments,
the cells were serum-starved.
Measurement of Cytokines in Plasma and
Culture Supernatants
Concentrations of Ang II, IL-6, IL-1, TNF-, and TGF-1 were
measured in plasma and culture supernatants by ELISA kits
(Bertin, DY 406, DY 401, DY 410 and DY 1679, R&D
systems).13
Confocal Imaging
Cells or tissues were observed after 4% paraformaldehyde fixa-
tion and revealed using either a mouse monoclonal anti–FLAG
M2 (Sigma, 1:100), a rabbit anti-GFP antibody (Santa Cruz
Biotechnology, 1:100), a monoclonal anti-5-HT2BR antibody
(Pharmingen,1:100), a rabbit anti-AT1R (N-10, Santa Cruz Bio-
technology, 1:100) or a rabbit anti-Vimentin (Santa Cruz Bio-
technology, 1:200).
Immunoprecipitation and Western Blotting
Serum-starved cells were homogenized at 4°C in RIPA buffer,
centrifuged at 10 000g, and incubated with either anti-FLAG affinity
matrix (40 L, Sigma) overnight at 4°C or a monoclonal anti–5-
HT2BR antibody (Pharmingen, 2 g). Western blot analysis of
immunoprecipitated samples was performed on SDS-PAGE 10%
gels and revealed using either a rabbit anti-GFP antibody (Santa Cruz
Biotechnology, 1:1000) or a rabbit anti-AT1R (N-10, Santa Cruz
Biotechnology, 1:1000).
Data Analysis and Statistics
All results are expressed as meansSEM. Different groups were
compared through 1-way ANOVA, followed by Newman–Keuls test.
All calculations were performed using the GraphPad Prism 4.0 program.
Results
Expression of 5-HT2BRs by Noncardiomyocytes Is
Required for ISO-Induced Cardiac Hypertrophy
We first verified the expression of 5-HT2BRs and AT1Rs either
by immunohistochemistry of human adult left ventricles (Figure
Figure 3. Expression of 5-HT2BRs by noncardiomyocytes is required for ISO-induced cardiac hypertrophy in vivo. In the different trans-
genics (Tg; 5-HT2B
/; Tg; 5-HT2B
/; Tg; 5-HT2B
/; and global 5-HT2B
/ mice), ISO infusion led to a significant increase in left ven-
tricular mass-to-body weight ratio (LVM/BW) (a) from 0 (D0) (black bars) to 7 days of ISO (30 g/g per day) infusion (ISO D7) (white
bars), as determined by echocardiography, and a significant decrease in fractional shortening (FS) (b) or in systolic ejection volume
(SEV) (c), only in Tg; 5-HT2B
/ and Tg; 5-HT2B
/ but not in Tg; 5-HT2B
/ mice expressing 5-HT2BRs solely in cardiomyocytes or
global 5-HT2B
/ mice. The cytokine IL-6 (d), IL-1 (e), and TGF- (f) plasma levels are also increased only in Tg; 5-HT2B
/ and Tg;
5-HT2B
/ but not in Tg; 5-HT2B
/ mice expressing 5-HT2BRs solely in cardiomyocytes or global 5-HT2B
/ mice. Values are
meansSEM. *P0.05, D0 vs D7 ISO (30 g/g per day) (n6 to 8 mice).
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1a and 1b) or by binding assays on primary cultures of wild-type
and 5-HT2BR/ mice (Figure 1d and 1e). Interestingly,
5-HT2BRs were found mainly colocalized with AT1Rs and
vimentin (a marker of cardiac fibroblasts) in human heart
sections. To assess whether 5-HT2BR expression in cardiomyo-
cytes is required for left ventricular hypertrophy, global
5-HT2BR/mice were crossed with transgenic mice expressing
5-HT2BRs selectively in cardiomyocytes via the cardiomyocyte-
specific -MHC promoter (Tg) (Figure 2a).22 After genotyping,
the 4 resulting strains (5-HT2B/, Tg; 5-HT2B/, Tg;
5-HT2B/, Tg; 5-HT2B/, and 5-HT2B/ [Figure 2b]) were
assessed for cardiac 5-HT2BR expression (Figure 2c). As ex-
pected after ISO infusion, a similar heart rate increase was
observed in all 4 genotypes (25%) (supplemental Table I). By
echocardiography, ISO infusion led to cardiac hypertrophy in
Tg; 5-HT2B/ and in Tg; 5-HT2B/ mice as shown by
increased left ventricular mass-to-body weight ratio (30%)
(Figure 3a and supplemental Table I). However, Tg; 5-HT2B/
mice expressing 5-HT2BRs solely in cardiomyocytes were, like
global 5-HT2B/ mice, resistant to ISO-induced cardiac hyper-
trophy. ISO-induced impairment of left ventricle contractility
was observed in the Tg; 5-HT2B/ and in the Tg; 5-HT2B/
mice, as demonstrated by a decrease of both fractional shorten-
ing and systolic ejection volume in these 2 groups. Conversely,
ISO did not modify ventricular functions in Tg; 5-HT2B/ or in
global 5-HT2B/ mice (Figure 3b and 3c). Importantly, Ang II
plasma level was not increased at 7 days of ISO-infusion in any
mice (40532, versus 35461 fg/mL, P0.05, n6 per geno-
type each in triplicate). However, ISO infusion led to significant
increases in plasma concentrations of TNF- (1.4-fold over
basal; supplemental Figure IV), IL-6 (2.5-fold over basal), IL-1
(2.8-fold over basal), and TGF- (2.5-fold over basal) in Tg;
5-HT2B/ and in Tg; 5-HT2B/ mice (Figure 3d and 3f).
Furthermore, Tg; 5-HT2B/ mice expressing 5-HT2BRs only in
cardiomyocytes were, like global 5-HT2B/ mice, resistant to
ISO-induced increase in plasma cytokines.
Angiotensinogen, AT1Rs, and 5-HT2BRs Are
Required for ISO-Induced Cytokine Release
in Noncardiomyocytes
Interestingly, primary cultures of adult noncardiomyocytes
isolated from Angiotensinogen mutant mice (Agt/), which
are unable to generate Ang II,27 did not exhibit any increase
in cytokine release after ISO stimulation, whereas Ang II
(100 nmol/L) significantly increased concentrations of IL-6
(4.7-fold over basal), IL-1 (4.1-fold), and TNF- (1.6-fold)
at 4 hours, as did 5-HT (1 mol/L) stimulation (Figure 4a and
4d and supplemental Figure IV, a). Furthermore, ISO stimu-
lation of wild-type cardiac fibroblasts elicited a significant
increase in the release of Ang II (88324 fg/mL at 4 hours
versus 1907 fg/mL at 0 hour; n4 independent determina-
tions in triplicate; P0.05) but not of 5-HT (1 nmol/L). The
potent and selective AT1R antagonist ZD7155 at 100 nmol/L
(supplemental Figure I, A and C) significantly reduced
ISO-induced cytokine release (IL-6, 4-, IL-1, 1.8-, and
TNF-; 2.3-fold,) at 8 hours (Figure 4b through 4e and
Figure 4. 5-HT2BRs and AT1Rs are required for ISO-induced cytokine release in cardiac fibroblast culture. A significant increase in IL-6
(a) and IL-1 (d) cytokines could not be observed in adult cardiac fibroblasts isolated from Agt/ mice unable to generate Ang II after
stimulation with ISO (10 mol/L) () but was observed after a 4-hour Ang II (100 nmol/L) (f) or 5-HT (1 mol/L) (F) stimulation. Simi-
larly, IL-6 (b) and IL-1 (e) cytokines were significantly increased in adult cardiac fibroblasts isolated from wild-type (WT) (f) mice after
a height-hour stimulation with ISO (10 mol/L), but not after preincubation with ZD7155 (ZD) (100 nmol/L) (F), for 30 minutes. Finally,
stimulation with Ang II (100 nmol/L) increased IL-6 (c) and IL-1 (f) supernatant concentrations in adult cardiac fibroblasts from wild-
type mice (5-HT2B/) (/, f), but not after 30 minutes of preincubation with the 5-HT2BR antagonist SB206553 (SB) (100 nmol/L)
(E) or from global mutant for 5-HT2BRs (5-HT2B
/) (/; ). Results are meansSEM expressed in pg/mL of cardiac fibroblasts
supernatants (n3 independent fibroblast cultures each determination in triplicate). *P0.05 vs antagonist-treated.
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supplemental Figure IV, b) but not basal cytokine levels.
Either genetic or pharmacological (using the potent and
selective antagonist SB206553; supplemental Figure I, B
and D) blockade of 5-HT2BRs inhibited Ang II–induced
cytokine release in adult cardiac fibroblasts (Figure 4c and
4f and supplemental Figure IV, c). Moreover, we also
verified that 5-HT2BRs were required for cytokine produc-
tion by newborn cardiac fibroblasts (supplemental Figure
III, E and F).
5-HT2BRs and AT1Rs Share a Common Epidermal
Growth Factor Receptor Transactivation
Pathway–Mediating Cytokine Release
Similar to the effects of 5-HT2BR antagonists on Ang II
action, ZD7155 (100 nmol/L) significantly reduced 5-HT-
induced cytokine release (Figure 5a through 5c and supple-
mental Figure IV, d). In noncardiac cells, activation of AT1Rs
or -ARs has been shown to induce shedding of heparin-
binding epidermal growth factor (HB-EGF) through activa-
Figure 5. Ang II– or 5-HT–induced cytokine release is mediated by EGF-R transactivation. Wild-type (/) adult cardiac fibroblasts
were preincubated with various inhibitors (SB206553 [100 nmol/L], a selective 5-HT2BR antagonist [n4]; ZD7155 [100 nmol/L], a selec-
tive AT1R antagonist [n3]; AG1478 [100 nmol/L], a selective inhibitor of EGF-R [n3]; GM6001 [100 nmol/L], an MMP inhibitor [n5]
[see dose response in supplemental Figure III, C and D]; PP2 [200 nmol/L], a Src inhibitor [n3]; PD098059 [10 mol/L], a specific in-
hibitor of ERK1/2 [n3]; SB203580 [10 mol/L], a specific inhibitor of p38 [n3]) for 30 minutes, stimulated for 4 hours with Ang II (100
nmol/L) (gray bars) or 5-HT (1 mol/L) (black bars) or not (n10) (nnumber of independent fibroblasts culture, each determination in
triplicate). Cultures of HB-EGF mutant fibroblasts (/HB-EGF) were also stimulated with EGF (10 ng/mL), Ang II (100 nmol/L) or 5-HT
(1 mol/L) during 4 hours (n4). IL-6 (a), IL-1 (b), and TGF- (c) supernatant concentrations were measured by ELISA. Results are
meansSEM expressed in pg/mL of cardiac fibroblasts supernatants. **P0.001, *P0.05 vs control; #P0.05 vs Ang II or 5-HT.
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tion of matrix metalloproteinases (MMPs) and subsequent
activation of the epidermal growth factor receptor (EGF-R), a
phenomenon called transactivation.28,29 In adult cardiac fibro-
blasts in the presence of AG1478 (an EGF-R blocker, 100
nmol/L), either Ang II– or 5-HT–induced release of IL-6,
TNF-, and IL-1 was totally prevented and that of TGF-
only partially (Figure 5a through 5c and supplemental Figure
IV, d). Cytokine release stimulated by either Ang II or 5-HT
was totally abrogated in adult cardiac fibroblasts prepared
from mice lacking HB-EGF, although EGF stimulation (10
ng/mL) led to normal cytokine release (Figure 5a through 5c
and supplemental Figure IV, d). GM6001 (an MMP inhibitor,
100 nmol/L) (supplemental Figure 3, C and D) or PP2 (a Src
inhibitor, 200 nmol/L) totally prevented Ang II– and 5-HT–
induced cytokine release by cardiac fibroblasts (Figure 5a
through 5c and supplemental Figure IV, d). Interestingly, a
strong reduction of Ang II– and complete reduction of
5-HT–induced cytokine release were induced by the p38
inhibitor SB203580 (10 mol/L). Conversely, the extracellu-
lar signal-regulated kinase (ERK)1/2 inhibitor PD098059
(10 mol/L) did not affect Ang II– or 5-HT-induced IL-6,
IL-1, or TGF- release and only slightly reduced TNF-
cytokine release (Figure 5a through 5c and supplemental
Figure IV, d).
5-HT2BRs and AT1Rs Colocalize
and Coimmunoprecipitate
By confocal microscopy, we first observed membrane colo-
calization of 5-HT2BRs and AT1Rs in rat cardiac fibroblasts
(Figure 6a). After immunoprecipitation of neonatal rat car-
diac fibroblast extracts with an anti-5-HT2BR antibody, we
detected bands of 41 to 43 kDa (expected molecular mass for
AT1Rs) similar to those observed by direct Western blot
analysis (Figure 6a) with an anti-AT1R antibody. We further
confirm these putative interactions, using HEK293 trans-
fected cells with FLAG-tagged human AT1Rs and CFP-
tagged human 5-HT2BRs, that showed membrane colocal-
ization (Figure 6b). After immunoprecipitation with an
anti-FLAG antibody, we probed Western blots of immu-
noprecipitations with an anti-GFP antibody. We detected a
Figure 6. 5-HT2BRs and AT1Rs colocalize and
coimmunoprecipitate in transfected cells. a, Fixed
newborn rat cardiac fibroblast primary culture were
immunostained using antisera against 5-HT2BR or
AT1R. Single confocal plane observation reveals
that 5-HT2BR localization (5-HT2BR) is mainly colo-
calized (merge) with AT1R-positive cells (AT1R); top
scale bar, 2 m; bottom, higher magnification
(scale bar, 1 m). Newborn cardiac fibroblast (CF)
were immunoprecipitated with anti–5-HT2BR anti-
body (IP) (left lane), and then crude extract (right
lane) or immunoprecipitate were immunoblotted
(IB) using anti-AT1R antibody. b, Top, HEK293
cells were cotransfected with 5-HT2BR-CFP and
AT1R-Flag. Single confocal plane observation
reveals the 5-HT2BR-CFP localization (2B-CFP),
AT1R-Flag localization (AT-1-Flag), and their colo-
calization by overlay (merge). Scale bar, 2 m.
Bottom, HEK293 cells, nontransfected (NT) or
transfected with 5-HT2BR-CFP (2B-CFP), AT1R-
Flag (AT1-Flag), or 5-HT2BR-CFP in combination
with AT1R-Flag were immunoprecipitated with anti-
Flag antibody. Immunoprecipitates (IP) anti-Flag
were immunoblotted using anti-CFP antibody.
Blots are representative of 3 independent
experiments.
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single band of 80 kDa (the expected molecular mass of the
CFP-5-HT2BR) only in cotransfected cells (Figure 6b).
These results strongly suggest that AT1Rs and 5-HT2BRs
colocalize and may directly interact in common signaling
complexes in transfected cells.
5-HT2BR Overexpression in Human Heart Failure
Because 5-HT2BRs were also expressed in both human
cardiac fibroblasts and cardiomyocytes (Figure 1), we as-
sessed a putative contribution of 5-HT2BRs in human CHF.
We looked for 5-HT2BR expression in left ventricular biop-
sies of 16 CHF patients, compared to 7 normal control
subjects. Expression of 5-HT2BRs, obtained from biopsies of
left ventricles, were found to be significantly elevated in
samples from failing hearts (Figure 7a). This increase appears
to be independent of cardiomyopathy etiology, severity of the
disease, or treatments (supplemental Table II). However,
significant correlations were found between cardiac 5-HT2BR
expression levels and plasma concentrations of either norepi-
nephrine, IL-6, TGF-, or TNF- in CHF patients (Figure 7b,
7c, and 7e and supplemental Figure IV, e) and reciprocally
(Figure 7d and 7f and supplemental Figure IV, f) but not in
controls (supplemental Table II). Taken together, these data
support the notion that 5-HT2BR expression is linked to
cardiac cytokine production during the sympathetic overac-
tivity associated with CHF.
Discussion
In light of our previous reports, 5-HT2BRs participate in
trophic responses of the myocardium by acting directly on
cardiomyocytes21,22 or indirectly on noncardiomyocytes
Figure 7. The overexpression of 5-HT2BRs observed in human cardiac hypertrophy is correlated with plasma norepinephrine and cyto-
kine levels. a, Expression of 5-HT2BRs (Bmax), obtained from biopsies of left ventricles, was found to be significantly elevated and is
expressed the average of subepicardial, subendocardial, and midventricle biopsies. Correlations between the cardiac 5-HT2BR expres-
sion levels (in fmol/mg of proteins) and the plasma levels (in pg/mL) of either norepinephrine (b), IL-6 (c), TGF- (e), or TNF- (Supple-
mental Figure 4f) are shown. Similarly, correlations between the plasma levels of norepinephrine with either IL-6 (d), TGF- (f), or TNF-
(Supplemental Figure 4g), are given. Probability value (p) and Spearman rank correlation (r) are presented.
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through the release of paracrine factors induced by chronic
ISO stimulation.13 By reexpressing the 5-HT2BR selectively
into cardiomyocytes in a 5-HT2BR–null background, we
describe here for the first time that its expression by noncar-
diomyocytes is absolutely required for ISO-induced cardiac
hypertrophy. The ISO-mediated increases in TNF-, TGF-,
IL-6, and IL-1 plasma levels observed in the wild-type mice
also require 5-HT2BR expression in noncardiomyocytes.
No increase in plasma Ang II could be detected after ISO
infusion in mice but Ang II can be produced in the heart
through a local renin-angiotensin system.30 Interestingly,
angiotensinogen mRNA and protein levels are increased by
-AR stimulation in neonatal cardiac fibroblasts,31 which
were shown, as opposed to cardiomyocytes, to serve as the
predominant source of IL-6 after ISO stimulation in mouse
myocardium. In our study, we uncover the Ang II/AT1R axis
critical role for ISO-induced cytokine release in adult cardiac
fibroblasts as validated by several observations. (1) A signif-
icant increase in Ang II, but not in 5-HT, was detected in
supernatants of adult mouse cardiac fibroblast culture after
ISO stimulation. (2) This peak of Ang II release occurs at 4
hours of ISO stimulation, similar to that of cytokines after
direct Ang II stimulation. (3) The cytokine release peak
following ISO stimulation occurred only after 8 hours,
suggesting a multistep process. (4) Consistent with these
results, Agt/ cardiac fibroblasts did not release cytokines
on ISO stimulation, but cytokine release in these cells was
similar to wild-type cells when stimulated with Ang II or
5-HT. (5) Finally, using ZD7155, we show that AT1Rs are
also required for ISO-induced cytokine release. Together,
these data reveal, for the first time, that ISO-dependent Ang
II production by cardiac fibroblasts leading to the autocrine
AT1R stimulation is absolutely required for hypertrophic
cytokine release in heart.
The present report addresses unknowns regarding the
AT1R and 5-HT2BR signaling pathway(s) controlling cyto-
kine release in cardiac fibroblasts. In the present work, we
demonstrate that expression of HB-EGF and Src activity are
critical for either an Ang II– or a 5-HT–dependent cytokine
release process. We show that MMPs are responsible for
HB-EGF shedding and subsequent EGF-R transactivation
that is induced by GPCR agonists such as Ang II or 5-HT.32,33
TNF-–converting enzyme (TACE) (ADAM-17) was found
to control HB-EGF shedding in fibroblasts,34 and a recent
report indicated that 5-HT2BRs can directly regulate this
enzyme activity in neuronal cells.35 Our work also highlights
the importance of p38 but not ERK1/2 pathway for cytokine
release. In summary, our data support the following epistatic
relationships (Figure 8 and online data and video): ISOfAng
IIf5-HT2BAT1RsfSrcfMMPsfHB-EGFfErbB-1/4-
Rsfp38fIL-6, TNF-, TGF-, and IL-1 release. All of
these findings support that AT1Rs and 5-HT2BRs share
common EGF-R-dependent signaling pathways in adult car-
diac fibroblasts.
Blockade of 1 of the 2 receptors prevents cytokine release
induced by the other receptor, supporting interactions be-
tween 5-HT2BRs and AT1Rs. Using coimmunolocalization
and a pull-down assay, we show that the 2 receptors interact
in a common cell compartment. Recently, reports have
suggested that GPCRs exist in heterodimeric complexes that
may play a key role in receptor maturation and trafficking to
the plasma membrane and/or signaling (for review, see
Bulenger et al36). The protein network associated with the C
terminus of the 5-HT2Rs includes scaffolding proteins con-
taining 1 or several PDZ domains, signaling proteins and
proteins of the cytoskeleton that may be involved in signaling
complexes.37 More work will be necessary to conclude
whether in vivo interactions between AT1Rs and 5-HT2BRs
are direct or mediated by adaptor proteins. Only a few reports
have described an inhibitory mechanism in trans between 2
GPCRs. To our knowledge, this process was first described
between AT1Rs and 2-ARs in COS-7 cells that express
equal endogenous levels of AT1Rs and 2-ARs and was also
shown to occur in adult cardiomyocytes.38 Together, our
findings are consistent with the hypothesis that AT1Rs and
5-HT2BRs exist in common signaling complexes and that they
may interact together.
The increase of 5-HT2BR sites in biopsies of left ventricles
from CHF patients that we observed appears independent of
the type of cardiopathy, its duration, or the treatments
(including  blockers or ACE inhibitors). In recent cardiac
transcriptome analysis, an increase in 5-HT2BR mRNA was
also reported in human39 or rat40 failing heart tissue, during
the functional recovery of end-stage human heart failure,41
and in rats after banding of the ascending aorta.42,43 The
significant correlation between 5-HT2BR expression and cy-
tokines IL-6, TNF-, or TGF- plasma levels supports, in
humans, our findings in mice. Interestingly, the significant
correlations with sympathetic activity found in patients indi-
cate that 5-HT2BRs are as well required for adrenergic-
dependent cytokines production in humans. A cardiac hyper-
trophy–associated switch of adult to fetal genes has been
reported. It is tempting to speculate that similar mechanisms
might be operative at 5-HT2B receptor expression, which is
expressed in embryonic heart. Sympathetic overstimulation
Figure 8. Deduced signaling pathway for cytokine production
after 5-HT or Ang II stimulation in adult cardiac fibroblasts.
Stimulation of -ARs on cardiac fibroblasts by ISO leads to the
release of Agt-dependent Ang II that stimulates the AT1R-5-
HT2BR complexes activating MMPs, which induces the pro-HB-
EGF cleavage. The mechanism that leads to MMPs activation
by AT1Rs or 5-HT2BRs involves Src. Soluble HB-EGF activates
ErbB-Rs to induce cytokine release via p38 mitogen-activated
protein kinase activation. Released cytokines and HB-EGF bind
their receptors in cardiomyocytes to activate hypertrophy in a
paracrine way (see also the online data supplement and Movie).
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may also participate via cAMP-dependent regulation as an
autocrine regulatory loop.35
In summary, our data indicate that a selective 5-HT2BR
antagonist blocks both Ang II and adrenergic adverse effects
in pathological conditions with no alterations of hemodynam-
ics or blood pressure.
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